RWS of Inetetamab HER2 Positive Advanced Breast Cancer

Zhiyong Yu

Status: Unknown

Conditions: HER2-positive Advanced Breast Cancer

Treatments: Drug: Inetetamab

Study type: Observational

Funder types: Other

Identifiers

NCT04963608

RSINETE

Details and patient eligibility

About

This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.

Enrollment: 100 estimated patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with stage IV breast cancer
2. Patients with HER2 positive status
3. Patients that received Inetetamab
4. Patients that began Inetetamab therapy prior to June 30, 2021.

Exclusion criteria

Patients treated with an investigational anticancer agent Inetetamab

Trial design

100 participants in 1 patient group

non-interventional study

Description:

Her2 positive ABC patients who have received Inetetamab in the metastatic setting.

Treatment:

Drug: Inetetamab